Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.65 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178625 | 1.00 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| Hydrochloric Acid SCHEMBL23524368 | 0.98 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| Methamphetamine SCHEMBL28184718 | 0.90 | SIGMAR1 (0.84) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL765297 | 0.82 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| Pholedrine SCHEMBL119262 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL7316113 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| SCHEMBL11265489 | 0.80 | CYP2D6 (0.68) | TAAR1SLC18A2SIGMAR1SLC6A4CYP2D6 | |
| SCHEMBL18211455 | 0.80 | CYP1A2 (0.68) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| SCHEMBL21286088 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB | |
| SCHEMBL178533 | 0.80 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039009-B1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2019-05-01 | — | — | EP | disclosed |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-15 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | MAOB, MAOA, COMT | TAAR1 1406/4885SLC18A2 907/4885SIGMAR1 2039/4885 |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | TAAR1 195/4885SLC18A2 676/4885SIGMAR1 1095/4885 |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | TAAR1 195/4885SLC18A2 676/4885SIGMAR1 1095/4885 |
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BAX, API5, BCL2 | TAAR1 4852/4885SLC18A2 4765/4885SIGMAR1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.